407 related articles for article (PubMed ID: 23797000)
1. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.
Koreth J; Pidala J; Perez WS; Deeg HJ; Garcia-Manero G; Malcovati L; Cazzola M; Park S; Itzykson R; Ades L; Fenaux P; Jadersten M; Hellstrom-Lindberg E; Gale RP; Beach CL; Lee SJ; Horowitz MM; Greenberg PL; Tallman MS; DiPersio JF; Bunjes D; Weisdorf DJ; Cutler C
J Clin Oncol; 2013 Jul; 31(21):2662-70. PubMed ID: 23797000
[TBL] [Abstract][Full Text] [Related]
2. Optimal positioning of hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes.
Abel GA; Koreth J
Curr Opin Hematol; 2013 Mar; 20(2):150-6. PubMed ID: 23298879
[TBL] [Abstract][Full Text] [Related]
3. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
4. CD34
Barba P; Martino R; Zhou Q; Cho C; Castro-Malaspina H; Devlin S; Esquirol A; Giralt S; Jakubowski AA; Caballero D; Maloy M; Papadopoulos EB; Piñana JL; Fox ML; Márquez-Malaver FJ; Valcárcel D; Solano C; López-Corral L; Sierra J; Perales MA
Biol Blood Marrow Transplant; 2018 May; 24(5):964-972. PubMed ID: 29305194
[TBL] [Abstract][Full Text] [Related]
5. Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?
Zeidan AM; Gore SD
Expert Rev Hematol; 2013 Oct; 6(5):539-42. PubMed ID: 24093972
[TBL] [Abstract][Full Text] [Related]
6. Survival benefits from reduced-intensity conditioning in allogeneic stem cell transplantation for young lower-risk MDS patients without significant comorbidities.
Lee SE; Kim YJ; Yahng SA; Cho BS; Eom KS; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Lee JW; Min WS; Park CW
Eur J Haematol; 2011 Dec; 87(6):510-20. PubMed ID: 21883477
[TBL] [Abstract][Full Text] [Related]
7. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
Zhang Z; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
[TBL] [Abstract][Full Text] [Related]
8. Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS?
El-Jawahri A; Kim HT; Steensma DP; Cronin AM; Stone RM; Watts CD; Chen YB; Cutler CS; Soiffer RJ; Abel GA
Bone Marrow Transplant; 2016 Aug; 51(8):1121-6. PubMed ID: 26999469
[TBL] [Abstract][Full Text] [Related]
9. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
[TBL] [Abstract][Full Text] [Related]
10. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
[TBL] [Abstract][Full Text] [Related]
11. Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Damaj G; Mohty M; Robin M; Michallet M; Chevallier P; Beguin Y; Nguyen S; Bories P; Blaise D; Maillard N; Rubio MT; Fegueux N; Cornillon J; Clavert A; Huynh A; Adès L; Thiébaut-Bertrand A; Hermine O; Vigouroux S; Fenaux P; Duhamel A; Yakoub-Agha I
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1349-55. PubMed ID: 24838178
[TBL] [Abstract][Full Text] [Related]
12. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.
Martino R; Iacobelli S; Brand R; Jansen T; van Biezen A; Finke J; Bacigalupo A; Beelen D; Reiffers J; Devergie A; Alessandrino E; Mufti GJ; Barge R; Sierra J; Ruutu T; Boogaerts M; Falda M; Jouet JP; Niederwieser D; de Witte T;
Blood; 2006 Aug; 108(3):836-46. PubMed ID: 16597592
[TBL] [Abstract][Full Text] [Related]
13. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study.
Bejanyan N; Zhang M; Bo-Subait K; Brunstein C; Wang H; Warlick ED; Giralt S; Nishihori T; Martino R; Passweg J; Dias A; Copelan E; Hale G; Gale RP; Solh M; Kharfan-Dabaja MA; Diaz MA; Ganguly S; Gore S; Verdonck LF; Hossain NM; Kekre N; Savani B; Byrne M; Kanakry C; Cairo MS; Ciurea S; Schouten HC; Bredeson C; Munker R; Lazarus H; Cahn JY; van Der Poel M; Rizzieri D; Yared JA; Freytes C; Cerny J; Aljurf M; Palmisiano ND; Pawarode A; Bacher VU; Grunwald MR; Nathan S; Wirk B; Hildebrandt GC; Seo S; Olsson RF; George B; de Lima M; Hourigan CS; Sandmaier BM; Litzow M; Kebriaei P; Saber W; Weisdorf D
Transplant Cell Ther; 2021 Jan; 27(1):68.e1-68.e9. PubMed ID: 33010430
[TBL] [Abstract][Full Text] [Related]
14. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
15. The evolution of hematopoietic SCT in myelodysplastic syndrome.
Kindwall-Keller T; Isola LM
Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
[TBL] [Abstract][Full Text] [Related]
16. Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System.
Della Porta MG; Jackson CH; Alessandrino EP; Rossi M; Bacigalupo A; van Lint MT; Bernardi M; Allione B; Bosi A; Guidi S; Santini V; Malcovati L; Ubezio M; Milanesi C; Todisco E; Voso MT; Musto P; Onida F; Iori AP; Cerretti R; Grillo G; Molteni A; Pioltelli P; Borin L; Angelucci E; Oldani E; Sica S; Pascutto C; Ferretti V; Santoro A; Bonifazi F; Cazzola M; Rambaldi A
Leukemia; 2017 Nov; 31(11):2449-2457. PubMed ID: 28321120
[TBL] [Abstract][Full Text] [Related]
17. Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.
Nakamura R; Saber W; Martens MJ; Ramirez A; Scott B; Oran B; Leifer E; Tamari R; Mishra A; Maziarz RT; McGuirk J; Westervelt P; Vasu S; Patnaik M; Kamble R; Forman SJ; Sekeres MA; Appelbaum F; Mendizabal A; Logan B; Horowitz M; Cutler C
J Clin Oncol; 2021 Oct; 39(30):3328-3339. PubMed ID: 34106753
[TBL] [Abstract][Full Text] [Related]
18. Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 study rationale, design, and methods.
Saber W; Le Rademacher J; Sekeres M; Logan B; Lewis M; Mendizabal A; Leifer E; Appelbaum FR; Horowitz MM; Nakamura R; Cutler CS
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1566-72. PubMed ID: 24972249
[TBL] [Abstract][Full Text] [Related]
19. [New progress of study on hematopoietic stem cell transplantation for myelodysplastic syndromes].
Wu B; Wei Y; Zhang Q
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Apr; 20(2):510-3. PubMed ID: 22541129
[TBL] [Abstract][Full Text] [Related]
20. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Estey E; de Lima M; Tibes R; Pierce S; Kantarjian H; Champlin R; Giralt S
Blood; 2007 Feb; 109(4):1395-400. PubMed ID: 17038533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
